An observational study in Large B Cell Lymphoma, CAR T Cell Therapy and BTK Inhibitors, sponsored by The First Affiliated Hospital of Soochow University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by The First Affiliated Hospital of Soochow University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This observational study will examine outcomes of CAR-T cell therapy in adults with large B-cell lymphoma that has returned or has not responded to prior treatment. Participants will already have received bridging therapy that includes a BTK inhibitor before CAR-T cell infusion.
Researchers will compare outcomes between participants whose lymphoma responded to bridging therapy before CAR-T cell infusion and those whose lymphoma did not respond. The study will use medical records, imaging results, laboratory tests, treatment information, and follow-up data collected during usual care. It will not assign treatment, change medical care, or require extra tests or blood samples.
The study will assess lymphoma response after CAR-T cell therapy, safety, survival, and changes in routine blood markers of inflammation after CAR-T cell therapy.
886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.
This study's planned enrollment of 66 is below the median of 150 across 70 observational studies indexed under Lymphoma, B-Cell.
Browse Lymphoma, B-Cell studies →The First Affiliated Hospital of Soochow University is the lead sponsor of 264 studies on the registry; 151 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population comprises adults with relapsed or refractory large B-cell lymphoma (LBCL) who receive routine CAR-T cell therapy at a single center in China. Eligible patients receive BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy and have evaluable disease status after bridging therapy and before CAR-T cell infusion. Patients treated before ethics approval will be identified retrospectively from the center's CAR-T treatment records and routine medical records; eligible patients treated after ethics approval will be enrolled prospectively using the same criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort achieved complete response (CR) or partial response (PR). Treatments were determined as part of usual clinical care and were not assigned by the study.
Drug: BTK Inhibitor-Containing Bridging Therapy · Biological: CAR-T cell therapy
Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort had stable disease (SD) or progressive disease (PD). Treatments were determined as part of usual clinical care and were not assigned by the study.
Drug: BTK Inhibitor-Containing Bridging Therapy · Biological: CAR-T cell therapy
Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study.
CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study.
Best objective response rate after CAR-T cell infusion
The proportion of participants who achieve complete response (CR) or partial response (PR) at any time after CAR-T infusion and before first progression, death, initiation of new anti-lymphoma therapy, or last evaluable disease assessment. Participants without CR/PR before these events are classified as nonresponders; progression or death after CR/PR does not change responder status.
Time frame: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
Duration of response
Among participants who achieve CR or PR, duration of response is measured from the date of first documented CR or PR to disease progression or death from any cause, whichever occurs first. Participants without progression or death will be censored at the last evaluable disease assessment or before initiation of subsequent anti-lymphoma therapy.
Time frame: From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.
Complete response rate at 1 month after CAR-T cell infusion
Time frame: Approximately 1 month after CAR-T cell infusion.
Best complete response rate after CAR-T cell infusion
Time frame: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
Number of participants with CAR-T treatment-emergent adverse events
The number and percentage of participants with any adverse event occurring after CAR-T cell infusion will be reported. Safety events include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, prolonged cytopenia, death, and other clinically documented adverse events considered related to CAR-T cell therapy. CRS and ICANS will be graded according to ASTCT consensus criteria; other events will be collected from routine clinical, laboratory, and medical-record data.
Time frame: From CAR-T cell infusion to last follow-up.
Objective response rate at 1 month after CAR-T cell infusion
Time frame: Approximately 1 month after CAR-T cell infusion.
Objective response rate at 3 month after CAR-T cell infusion
Time frame: Approximately 3 months after CAR-T cell infusion.
Complete response rate at 3 months after CAR-T cell infusion
Time frame: 3 months after CAR-T cell infusion
Progression-free survival
Time frame: From CAR-T infusion to first progression, death, or last follow-up.
Overall survival
Time frame: From CAR-T infusion to death from any cause or last follow-up.
No study locations are listed for this record.
Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Soochow University →